Roque Matheus, Valle Marcello, Guimarães Fernando, Sampaio Marcos, Geber Selmo
ORIGEN - Center for Reproductive Medicine, Rio de Janeiro/RJ - Brazil.
ORIGEN - Center for Reproductive Medicine, Belo Horizone/MG - Brazil.
JBRA Assist Reprod. 2015 Aug 1;19(3):125-30. doi: 10.5935/1518-0557.20150028.
To evaluate the cost-effectiveness of freeze-all cycles when compared to fresh embryo transfer.
This was an observational study with a cost-effectiveness analysis. The analysis consisted of 530 intracytoplasmic sperm injection (ICSI) cycles in a private center in Brazil between January 2012 and December 2013. A total of 530 intracytoplasmic sperm injection (ICSI) cycles - 351 fresh embryo transfers and 179 freeze-all cycles - with a gonadotropin-releasing hormone (GnRH) antagonist protocol and day 3 embryo transfers.
The pregnancy rate was 31.1% in the fresh group and 39.7% in the freeze-all group. We performed two scenario analyses for costs. In scenario 1, we included those costs associated with the ICSI cycle (monitoring during controlled ovarian stimulation [COS], oocyte retrieval, embryo transfer, IVF laboratory, and medical costs), embryo cryopreservation of supernumerary embryos, hormone measurements during COS and endometrial priming, medication use (during COS, endometrial priming, and luteal phase support), ultrasound scan for frozen- thawed embryo transfer (FET), obstetric ultrasounds, and miscarriage. The total cost (in USD) per pregnancy was statistically lower in the freeze-all cycles (19,156.73 ± 1,732.99) when compared to the fresh cycles (23,059.72 ± 2,347.02). Even in Scenario 2, when charging all of the patients in the freeze-all group for cryopreservation (regardless of supernumerary embryos) and for FET, the fresh cycles had a statistically significant increase in treatment costs per ongoing pregnancy.
The results presented in this study suggest that the freeze-all policy is a cost-effective strategy when compared to fresh embryo transfer.
评估与新鲜胚胎移植相比,全胚冷冻周期的成本效益。
这是一项包含成本效益分析的观察性研究。分析纳入了2012年1月至2013年12月间巴西一家私立中心的530个卵胞浆内单精子注射(ICSI)周期。共有530个卵胞浆内单精子注射(ICSI)周期——351个新鲜胚胎移植周期和179个全胚冷冻周期——采用促性腺激素释放激素(GnRH)拮抗剂方案及第3天胚胎移植。
新鲜组的妊娠率为31.1%,全胚冷冻组为39.7%。我们针对成本进行了两种情景分析。在情景1中,我们纳入了与ICSI周期相关的成本(控制性卵巢刺激[COS]期间的监测、取卵、胚胎移植、体外受精实验室及医疗成本)、多余胚胎的胚胎冷冻保存、COS期间和子宫内膜准备期间的激素测量、药物使用(COS期间、子宫内膜准备期间及黄体期支持)、冻融胚胎移植(FET)的超声扫描、产科超声检查以及流产。与新鲜周期(23,059.72 ± 2,347.02美元)相比,全胚冷冻周期每例妊娠的总成本(以美元计)在统计学上更低(19,156.73 ± 1,732.99美元)。即使在情景2中,当向全胚冷冻组的所有患者收取冷冻保存(无论是否有多余胚胎)及FET的费用时,新鲜周期每例持续妊娠的治疗成本在统计学上仍有显著增加。
本研究结果表明,与新鲜胚胎移植相比,全胚冷冻策略具有成本效益。